Prezista (darunavir) / J&J 
Welcome,         Profile    Billing    Logout  
 32 Diseases   11 Trials   11 Trials   1696 News 


«12...345678910111213...2021»
  • ||||||||||  Prezista (darunavir) / J&J, Invirase (saquinavir) / Roche
    Journal:  Identification of Chymotrypsin-like Protease Inhibitors of SARS-CoV-2 Via Integrated Computational Approach. (Pubmed Central) -  Jun 22, 2021   
    Our results indicate that the identified compounds can inhibit the function of Chymotrypsin-like protease (3CL) of Coronavirus. Considering the severity of the spread of coronavirus, the current study is in-line with the concept of finding the new inhibitors against the vital pathway of the corona virus to expedite the process of drug discovery.
  • ||||||||||  ritonavir / Generic mfg.
    Journal:  Peptide-like and small-molecule inhibitors against Covid-19. (Pubmed Central) -  Jun 22, 2021   
    Cobicistat, ritonavir, lopinavir, and darunavir are in the top screened molecules from FDA approved drugs. The screened drugs and molecules may be helpful in fighting with SARS-CoV-2 after further studies.
  • ||||||||||  Tybost (cobicistat) / Gilead, Prezista (darunavir) / J&J, Prezcobix (darunavir/cobicistat) / Gilead, J&J
    Clinical, Observational data, Journal, Patient reported outcomes:  Patient-Reported Outcomes in an Observational Cohort of HIV-1-Infected Adults on Darunavir/Cobicistat-Based Regimens: Beyond Viral Suppression. (Pubmed Central) -  May 28, 2021   
    Switching to a cobicistat-boosted darunavir-based therapy led to overall increased patient satisfaction and reduced symptom burden when compared with previous regimens. The use of patient-reported outcomes in clinical daily practice could provide a useful tool towards achieving guideline goals to achieve "fourth 90", having 90% of virally suppressed patients with a good health-related quality of life.
  • ||||||||||  Prezista (darunavir) / J&J, Pifeltro (doravirine) / Merck (MSD), Intelence (etravirine) / J&J
    [VIRTUAL] HIV drug resistance patterns among highly treatment-experienced children, adolescents and young adults in sub-Saharan Africa () -  May 27, 2021 - Abstract #IASHIV2021IAS_HIV_1038;    
    We evaluated baseline drug resistance patterns in children, adolescents, and young adults enrolled in the New Horizon's study, which provides darunavir (DRV) and/or etravirine (ETR) to children failing second-line ART...For NNRTIs, high-level resistance was found for NVP in 80%, EFV in 58%, while 45% remained susceptible to second-generation NNRTIs, doravirine (DOR) and ETR. Highly treatment-experienced children/adolescents in SSA have accumulated high-level of resistance to NRTI, NNRTI, and commonly used PIs, but susceptibility to DRV and second generation NNRTI was retained in most.
  • ||||||||||  [VIRTUAL] HIV minority resistance variants partially explain genotypic-phenotypic discordance () -  May 27, 2021 - Abstract #IASHIV2021IAS_HIV_995;    
    Discordance, mostly represented by genotypic DR overestimation, was partially explained by NGS minority DR variants. This suggests that minority DR variants might help refine genotypic interpretation algorithms to avoid inappropriate choice of drugs; but also, existence of alternative explanations.
  • ||||||||||  Prezista (darunavir) / J&J, Tivicay (dolutegravir) / ViiV Healthcare
    [VIRTUAL] OPTIPRIM 2-ANRS trial comparing dolutegravir vs darunavir in acute HIV-1 infection () -  May 27, 2021 - Abstract #IASHIV2021IAS_HIV_869;    
    Adult patients with a recent/acute HIV1-infection were enrolled in OPTIPRIM-2-ANRS169 randomised open-label multicenter trial, if they had a western-blot <5 antibodies or immunoblot <3 antibodies dated less than 10 days ago and a detectable plasma-HIV-RNA. The dolutegravir-based regimen had a much faster and powerful effect on viral replication within the first weeks following acute HIV infection, when viral replication level is particularly high with a major risk of HIV transmission; but this was not enough to further reduce the viral reservoir size.
  • ||||||||||  hydroxychloroquine / Generic mfg., ritonavir / Generic mfg.
    Journal:  Anti-malarial Drugs are Not Created Equal for SARS-CoV-2 Treatment: A Computational Analysis Evidence. (Pubmed Central) -  May 25, 2021   
    Our data suggest that hydroxychloroquine may exert additional direct antiviral activity compared to chloroquine. In the absence of clinical studies comparing the efficacy of these two compounds, hydroxychloroquine may offer additional effects and may be considered as first choice.
  • ||||||||||  ribavirin / Generic mfg., ritonavir / Generic mfg.
    Journal:  Inhibition effects of eight anti-coronavirus drugs on glycosides metabolism and glycosidases in human gut microflora. (Pubmed Central) -  May 21, 2021   
    However, for the inhibition of darunavir and chloroquine on the metabolism of quercetrin, there was no correlation between gut microflora and α-rhamnosidase system. Assessing the risk of HDI mediated by glycosidases in gut microflora may be conducive to the safety and efficacy of combining traditional herbal and Western medicine for the treatment of patients with Covid-19.
  • ||||||||||  Prezista (darunavir) / J&J
    Journal:  Efficiency of antiviral treatment in COVID-19. (Pubmed Central) -  May 11, 2021   
    Antiviral therapy with LPV/r had some favorable results compared to DRV/r in patients with COVID-19. Both therapies were well tolerated.
  • ||||||||||  Tybost (cobicistat) / Gilead
    [VIRTUAL] Drug interactions and clinical impact of cobicistat () -  May 8, 2021 - Abstract #ECCMID2021ECCMID_543;    
      21 patients (12,7%) had clinical or blood test impact which forced a change in their treatment and 80 (48%) patients’ ART was modified to prevent future toxicity . Conclusions Cobicistat drug interactions are very common (50%) in between ART treated patients with comorbidities and/or toxic consumption antecedents, although the clinical impact is lower (12%). It is highly important to systematically review drug interactions when prescribing ART including a booster.
  • ||||||||||  Trileptal (oxcarbazepine) / Novartis
    Clinical, Journal:  Drug-Drug Interactions Between Antiretrovirals and Carbamazepine/Oxcarbazepine: A Real-Life Investigation. (Pubmed Central) -  May 6, 2021   
    Conclusions Cobicistat drug interactions are very common (50%) in between ART treated patients with comorbidities and/or toxic consumption antecedents, although the clinical impact is lower (12%). It is highly important to systematically review drug interactions when prescribing ART including a booster. Co-administration of carbamazepine or oxcarbazepine with atazanavir or dolutegravir should be avoided owing to the potential risk of virological failure; in case of these two drugs, the adoption of TDM is strongly advisable, eventually combining with increased antiretroviral doses.
  • ||||||||||  Prezista (darunavir) / J&J, Isentress (raltegravir) / Merck (MSD)
    Journal:  Antiretroviral therapy initiation is associated with decreased visceral and subcutaneous adipose tissue density in people living with HIV. (Pubmed Central) -  Apr 29, 2021   
    P=N/A
    Co-administration of carbamazepine or oxcarbazepine with atazanavir or dolutegravir should be avoided owing to the potential risk of virological failure; in case of these two drugs, the adoption of TDM is strongly advisable, eventually combining with increased antiretroviral doses. Following virologic suppression, lower SAT and VAT density was associated with greater plasma measures of systemic inflammation, lipid disturbances and insulin resistance independent of AT area, suggesting changes in AT density with ART may lead to adverse health outcomes independent of AT quantity.
  • ||||||||||  Arbidol (umifenovir) / Pharmstandard
    Clinical, Retrospective data, Journal:  Safety of protease inhibitors and Arbidol for SARS-CoV-2 pneumonia in Zhejiang Province, China. (Pubmed Central) -  Apr 19, 2021   
    Darunavir (DRV) is another protease inhibitor that blocks the binding of SARS-CoV-2 to human angiotensin-converting enzyme 2 (Omotuyi et al., 2020). The broad-spectrum antiviral drug Arbidol (umifenovir) also shows in vitro anti-SARS-CoV activity (Khamitov et al., 2008).
  • ||||||||||  bictegravir (GS-9883) / Gilead
    Journal:  Antiretroviral treatment for HIV infection: Swedish recommendations 2019. (Pubmed Central) -  Apr 13, 2021   
    As with previous publications, recommendations are evidence-graded in accordance with the Oxford Centre for Evidence Based Medicine. This document does not cover treatment of opportunistic infections and tumours.
  • ||||||||||  hydroxychloroquine / Generic mfg., ribavirin / Generic mfg.
    Review, Journal:  SARS-CoV-2: From the pathogenesis to potential anti-viral treatments. (Pubmed Central) -  Apr 7, 2021   
    The effectiveness rate and complications of these drugs can reveal new insights into the potential therapeutic goals for the disease. Moreover, lifestyle change can effectively prevent SARS-CoV-2 infection.
  • ||||||||||  ritonavir / Generic mfg.
    Journal:  Multidomain drug delivery systems of β-casein micelles for the local oral co-administration of antiretroviral combinations. (Pubmed Central) -  Apr 7, 2021   
    To simplify administration fixed-dose combinationshave been introduced, however, oral anti-HIV therapy still struggles with low oral bioavailability of many ARVs.This work investigated the co-encapsulation of two clinically relevant ARV combinations,tipranavir (TPV):efavirenz (EFV) anddarunavir (DRV):efavirenz (EFV):ritonavir (RTV),within the core of β-casein (bCN) micelles...At intestinal pH, the coating polymer dissolved and released the nanocarriers and content. Overall, our results confirm the promise of this flexible and modular technology platform for oral delivery of fixed dose combinations.
  • ||||||||||  Tybost (cobicistat) / Gilead, Prezista (darunavir) / J&J, Prezcobix (darunavir/cobicistat) / Gilead, J&J
    Review, Journal:  Management of Antiretroviral Therapy with Boosted Protease Inhibitors-Darunavir/Ritonavir or Darunavir/Cobicistat. (Pubmed Central) -  Apr 7, 2021   
    Regardless of the patient or type of virus, the combined regimens of DRV/COBI or DRV/RTV are available to clinicians, proving their effectiveness, with a major impact on HIV mortality/morbidity. This study presents current information on the pharmacokinetics, pharmacology, drug interactions, and adverse reactions of DRV; it not only compares the bioavailability, pharmacokinetic parameters, immunological and virological responses, but also the efficacy, advantages, and therapeutic disadvantages of DRV/COBI or DRV/RTV combinations.
  • ||||||||||  ritonavir / Generic mfg., amantadine / Generic mfg.
    Review, Journal:  A review: Mechanism of action of antiviral drugs. (Pubmed Central) -  Mar 26, 2021   
    An analysis of the action mechanism of known antiviral drugs concluded that they can increase the cell's resistance to a virus (interferons), suppress the virus adsorption in the cell or its diffusion into the cell and its deproteinisation process in the cell (amantadine) along with antimetabolites that causes the inhibition of nucleic acids synthesis. This review will address currently used antiviral drugs, mechanism of action and antiviral agents reported against COVID-19.